Biovica announced that the company has signed its second US hospital agreement for DiviTum® TKa with the largest healthcare provider in Missouri, a state covering about two percent of the US population. The healthcare provider operates 18 hospitals of which one is a National Cancer Institute (NCI) Comprehensive Cancer Center and has been a partner to Biovica during the clinical development of DiviTum® TKa.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 SEK | -4.58% | +7.28% | -33.72% |
Apr. 13 | Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024. | CI |
Apr. 12 | Biovica International AB Announces Divitum® Tka in Observational Trial | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.72% | 14.15M | |
-32.63% | 9.2B | |
-5.66% | 3.12B | |
+23.12% | 2.8B | |
-18.33% | 2.05B | |
-24.39% | 1.59B | |
+65.65% | 1.44B | |
+32.83% | 830M | |
-6.77% | 720M | |
-29.80% | 507M |
- Stock Market
- Equities
- BIOVIC B Stock
- News Biovica International AB
- Biovica Signs Second Agreement with US Healthcare Provider